Ofichem Acquires Meribel Pharma Solutions’ Uppsala Site
Ofichem, a European CDMO specialising in high-quality active pharmaceutical ingredients (APIs) and integrated drug development and manufacturing services, has acquired Meribel Pharma Solutions’ site in Uppsala, Sweden.
The Uppsala site, formerly part of Recipharm and known as OT Chemistry, specialises in small-scale, early-phase development work. The facility spans traditional small molecule and emerging modalities such as antibody-drug conjugates (ADCs), oligonucleotides and proteolysis-targeting chimeras (PROTACs), expanding Ofichem’s non-GMP capabilities in early-stage development.
“This acquisition is a strategic building block in Ofichem’s broader transformation,” said Weite H. Oldenziel, CEO and owner of Ofichem. “Our goal is to serve innovative biotech companies with agile, early-stage development solutions, and this site offers precisely the expertise and technologies we need to deliver on that vision.”
The site will operate in close coordination with Ofichem’s GMP manufacturing operations in Ter Apel, the Netherlands, creating a seamless path from early-stage research to commercial production. The acquisition also provides access to a portfolio of more than 40 biotech and mid-sized pharma clients, expanding Ofichem’s reach across the Nordic countries.
“We’re delighted to welcome the Uppsala team into the Ofichem family, and to expand our reach across new geographies and technologies,” said Alessia Cogotti, Managing Director at Ofichem. “This site strengthens our ability to support clients from idea to implementation, and everything in between.”
“We are proud to have found in Ofichem a reliable and respected partner who shares our values and unwavering focus on customer success,” said Bruce Vielle, CEO of Meribel. “This agreement is not only a positive step for both organizations but especially for the dedicated team and ongoing projects at the Uppsala site. Strategically, the partnership enables Meribel to sharpen its focus on advancing our drug product solutions, an area where we see increasing demand and opportunity."
The Meribel acquisition is a small-scale, strategic add-on, and the site will be integrated into Ofichem’s matrix structure, aligning under group-level leadership in operations, quality, research and development, and business development. Ofichem plans to further grow and expand its early-stage drug substance network, including evaluations of larger-scale GMP manufacturing sites in Europe and North America.
